T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
AGN
Allergan plc
AGN
|
+$1.66B |
| 2 |
Canadian Natural Resources
CNQ
|
+$759M |
| 3 |
Becton Dickinson
BDX
|
+$735M |
| 4 |
Ashland
ASH
|
+$669M |
| 5 |
Keysight
KEYS
|
+$573M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
RTX Corp
RTX
|
+$1.73B |
| 2 |
Ecolab
ECL
|
+$1.17B |
| 3 |
Crown Castle
CCI
|
+$906M |
| 4 |
Phillips 66
PSX
|
+$775M |
| 5 |
Gilead Sciences
GILD
|
+$756M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 20.28% |
| 2 | Consumer Discretionary | 14.05% |
| 3 | Financials | 13.42% |
| 4 | Industrials | 12.52% |
| 5 | Technology | 10.06% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1451
Theravance Biopharma
TBPH
$878M
| $5.12M | ﹤0.01% |
342,948
-2,097
| -0.6% | -$36.5K |
|
|
GLOP
1452
DELISTED
GASLOG PARTNERS LP
GLOP
| $5.11M | ﹤0.01% |
202,000
| – | – |
|
1453
Unisys
UIS
$210M
| $5.08M | ﹤0.01% |
172,339
-25,100
| -13% | -$631K |
|
1454
lululemon athletica
LULU
$13.6B
| $5.08M | ﹤0.01% |
91,000
| – | – |
|
|
PRFT
1455
DELISTED
Perficient Inc
PRFT
| $5.07M | ﹤0.01% |
272,100
-6,100
| -2% | -$101K |
|
|
NOAH
1456
Noah Holdings
NOAH
$588M
| $4.99M | ﹤0.01% |
238,741
-737,013
| -76% | -$12.8M |
|
|
BGC
1457
DELISTED
General Cable Corporation
BGC
| $4.98M | ﹤0.01% |
334,020
-350,630
| -51% | -$4.91M |
|
1458
Evercore
EVR
$12B
| $4.87M | ﹤0.01% |
92,976
-145,990
| -61% | -$7.31M |
|
1459
Cheniere Energy
LNG
$55B
| $4.87M | ﹤0.01% |
69,138
+4,533
| +7% | +$320K |
|
1460
Innoviva
INVA
$1.5B
| $4.85M | ﹤0.01% |
342,864
-21,330
| -6% | -$321K |
|
|
AUXL
1461
DELISTED
AUXILIUM PHARAMCEUTICALS INC
AUXL
| $4.82M | ﹤0.01% |
140,100
-17,500
| -11% | -$571K |
|
1462
Antero Resources
AR
$11.3B
| $4.75M | ﹤0.01% |
117,050
-241,274
| -67% | -$11.6M |
|
1463
Crawford & Co Class A
CRD.A
$627M
| $4.72M | ﹤0.01% |
551,356
+140,240
| +34% | +$1.16M |
|
1464
Reliance Steel & Aluminium
RS
$21.7B
| $4.7M | ﹤0.01% |
76,716
-2,046
| -3% | -$130K |
|
|
HEES
1465
DELISTED
H&E Equipment Services
HEES
| $4.69M | ﹤0.01% |
167,050
-457,780
| -73% | -$15.5M |
|
1466
YPF Sociedad Anonima American Depositary Shares (Each representing ten (10) Class D shares of Capital Stock)
YPF
$19.4B
| $4.69M | ﹤0.01% |
177,065
+56,165
| +46% | +$1.74M |
|
1467
Ligand Pharmaceuticals
LGND
$5.76B
| $4.61M | ﹤0.01% |
138,720
-9,779
| -7% | -$318K |
|
|
SGY
1468
DELISTED
Stone Energy
SGY
| $4.58M | ﹤0.01% |
4,773
+143
| +3% | +$172K |
|
|
DNR
1469
DELISTED
Denbury Resources, Inc.
DNR
| $4.56M | ﹤0.01% |
560,367
| – | – |
|
1470
Ardelyx
ARDX
$1.01B
| $4.55M | ﹤0.01% |
+241,016
| New | +$5.58M |
|
1471
Boot Barn
BOOT
$4.92B
| $4.55M | ﹤0.01% |
+250,100
| New | +$4.92M |
|
|
PLCM
1472
DELISTED
POLYCOM INC
PLCM
| $4.5M | ﹤0.01% |
333,624
+3,400
| +1% | +$43.4K |
|
1473
Chemed
CHE
$7.02B
| $4.49M | ﹤0.01% |
42,500
+8,500
| +25% | +$898K |
|
1474
Myriad Genetics
MYGN
$303M
| $4.35M | ﹤0.01% |
127,600
| – | – |
|
1475
Children's Place
PLCE
$53.4M
| $4.31M | ﹤0.01% |
75,650
-7,600
| -9% | -$393K |
|
Similar funds
T. Rowe Price Associates's Q4 2014 Portfolio in Review
As of Q4 2014, T. Rowe Price Associates held 2,627 positions worth $471B, up 2.8% from $458B the previous quarter. Its ten largest holdings account for 13% of the portfolio.
T. Rowe Price Associates's Q4 2014 filing shows 87 new, 929 increased, 999 reduced and 89 closed positions. Its largest new stake was Keysight: 17,553,953 shares worth $593M. The largest sale was RTX Corp, an estimated $1.73B.
By sector, the portfolio is most concentrated in Healthcare at 20% of assets, up from 19% a quarter earlier, followed by Consumer Discretionary and Financials.
- T. Rowe Price Associates's largest Q4 2014 buy was Keysight: 17,553,953 shares worth $593M.
- T. Rowe Price Associates added most to Allergan plc in Q4 2014, an estimated $1.66B increase.
- T. Rowe Price Associates's biggest Q4 2014 reduction was RTX Corp, cutting an estimated $1.73B.
- T. Rowe Price Associates fully exited ATHLON ENERGY INC COM in Q4 2014, selling an estimated $499M.
- T. Rowe Price Associates's ten largest holdings make up 13% of its $471B portfolio in Q4 2014.
- T. Rowe Price Associates opened 87 new positions and closed 89 in Q4 2014.
- T. Rowe Price Associates's portfolio value rose 2.8% quarter-over-quarter to $471B.
Based on T. Rowe Price Associates's 13F filing for Q4 2014, filed 13 Feb 2015.